PA
TEVA icon

PSI Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

PSI Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,000
Closed -$8K – 837
2022
Q2 		$8K Hold
1,000
– – ﹤0.01% 509
2022
Q1 		$9K Hold
1,000
– – ﹤0.01% 492
2021
Q4 		$8K Hold
1,000
– – ﹤0.01% 539
2021
Q3 		$10K Buy
+1,000
New +$9.36K ﹤0.01% 493
2020
Q1 		– Sell
-8,900
Closed -$87K – 530
2019
Q4 		$87K Buy
+8,900
New +$79.5K 0.06% 200

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

PSI Advisors's TEVA Position: Q3 2022 in Review

PSI Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2022, closing a stake of 1,000 shares — an estimated $8K sold.

PSI Advisors first reported a position in TEVA in Q4 2019 and held it in 5 quarters. The position peaked at $87K in Q4 2019. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

  • PSI Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • PSI Advisors sold 1,000 Teva Pharmaceuticals shares in Q3 2022, an estimated $8K.
  • PSI Advisors first reported a position in Teva Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • PSI Advisors's Teva Pharmaceuticals position peaked at $87K in Q4 2019.
  • 430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on PSI Advisors's 13F filing for Q3 2022, filed 20 Oct 2022.